Clinical trials have also explored the effects of other glycolysis inhibitors, such as lactate dehydrogenase A inhibitors and pyruvate dehydrogenase kinase inhibitors, which have shown promising anti-tumor activity in various cancer models, including non-small cell lung cancer (NSCLC) and HCC [130, 131]. The gene discussed is LDHA; the disease is non-small cell lung carcinoma.